Otsuka
#1757
Rank
$9.26B
Marketcap
Japan
Country
Mr. Tatsuo Higuchi (CEO, Pres & Representative Director)
Ms. Noriko Tojo (Exec. Director)
Mr. Yoshiro Matsuo (Exec. Deputy Pres & Director)
Summary
History
OPC's parent company Otsuka Holdings Co. Ltd. joined the Tokyo Stock Exchange through an initial public offering on December 15, 2010, at which time Otsuka Holdings was Japan's No.2 drug maker by sales after industry leader Takeda Pharmaceutical Company. The IPO debuted at $2.4 billion, making it the largest for a pharmaceutical company up to that time.
Otsuka Pharmaceutical Co. LTD Holdings
In 1955, the company started a football club called "Otsuka Pharmaceutical SC." In 2005 the name changed to Tokushima Vortis. The club is based in Naruto.In 2008, Otsuka Pharmaceutical Co. acquired 49% of Alma S.A., which is the parent company of CG Roxane.In March 2017, the company agreed to acquire Neurovance, Inc. for $250 million, gaining the firm’s Phase III-ready ADHD drug centanafadine . Otsuka's subsidiary Otsuka America will pay $100 million upfront for Neurovance, plus up-to $150 million in development and approval milestones. As a result of the transaction, Neurovance will operate as an indirect, wholly owned subsidiary.In July 2017, they bought DaiyaIn July 2018, Otsuka agreed to acquire Visterra for $430 million cash.
Mission
Vision
Key Team
Mr. Masayuki Kobayashi (Exec. Director)
Mr. Makoto Inoue (Exec. Director)
Ms. Yuko Makino (CFO & Exec. Director)
Tsuyoshi Nakamura (VP and Head of Fin. & Accounting)
Akiko Ryu (Sr. VP & Director of Human Resource Planning Department)
Mr. Shuichi Takagi (MD, CSO & Director)
Chiaki Sakurai (Sr. VP of Nutraceutical Bus., Global Strategy & Planning Headquarters)
Recognition and Awards
References
https://en.wikipedia.org/wiki/Otsuka_Pharmaceutical
https://in.investing.com/equities/otsuka-holdings-ltd
https://finance.yahoo.com/quote/4578.T/profile?p=4578.T
https://www.comparably.com/companies/otsuka-pharmaceutical/mission
https://www.crunchbase.com/organization/otsuka-pharmaceutical
Mr. Tatsuo Higuchi (CEO, Pres & Representative Director)
Ms. Noriko Tojo (Exec. Director)
Mr. Yoshiro Matsuo (Exec. Deputy Pres & Director)